| Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials HY Kuo, KA Khan, RS Kerbel Nature Reviews Clinical Oncology, 1-15, 2024 | | 2024 |
| Potentiating salvage radiotherapy in radiorecurrent prostate cancer through anti-CTLA4 therapy: Implications from a syngeneic model H Wang, L Gong, X Huang, SD White, HT Chung, D Vesprini, TN Petchiny, ... Cancer Research 84 (6_Supplement), 1353-1353, 2024 | | 2024 |
| Abstract A025: Combination of anti-CTLA4 and radiation induce synergistic tumor control in radiorecurrent prostate cancer H Wang, X Huang, SD White, L Gong, TN Petchiny, H Chung, E Fokas, ... Cancer Immunology Research 11 (12_Supplement), A025-A025, 2023 | | 2023 |
| Metronomic gemcitabine plus neratinib effectively inhibits the growth of human Her-2 positive breast cancer cells intracranially implanted into immunodeficient mice S Batson, A Sanchez, HM Padilla, DL Prospero, B Lugo, VV Lopez, ... Cancer Research 83 (7_Supplement), 3998-3998, 2023 | | 2023 |
| Implementing subtype‐specific pre‐clinical models of breast cancer to study pre‐treatment aspirin effects IS Miller, S Khan, LP Shiels, S Das, AC O'Farrell, K Connor, A Lafferty, ... Cancer Medicine 11 (20), 3820-3836, 2022 | | 2022 |
| ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth X Liu, S Chipurupalli, P Jiang, M Tavasoli, BH Yoo, M McPhee, ... Cell Death & Disease 13 (8), 687, 2022 | 4 | 2022 |
| On coalescent angiogenesis and the remarkable flexibility of blood vessels F Pezzella, RS Kerbel Angiogenesis, 1-3, 2022 | 6 | 2022 |
| Tumors resurrect an embryonic vascular program to escape immunity EJM Huijbers, KA Khan, RS Kerbel, AW Griffioen Science immunology 7 (67), eabm6388, 2022 | 34 | 2022 |
| Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma RS Kerbel, N Andre The Lancet 398 (10297), 278-279, 2021 | 7 | 2021 |
| Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer KA Khan, FTH Wu, W Cruz‐Munoz, RS Kerbel EMBO Molecular Medicine 13 (7), e08253, 2021 | 28 | 2021 |
| Dr. Isaiah “Josh” Fidler, 1936–2020: A Fond Remembrance R Kerbel Neoplasia (New York, NY) 22 (11), 604, 2020 | | 2020 |
| Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers L Schito, S Rey, P Xu, S Man, W Cruz‐Muñoz, RS Kerbel EMBO Molecular Medicine 12 (9), e11416, 2020 | 25 | 2020 |
| Abstract lb-079: Microbubble mediated focused ultrasound therapy enhances the antitumor potency and durability of anti-PD-L1 checkpoint blockade D Goertz, W Cruz, S Bulner, A Wright, R Kerbel Cancer Research 80 (16_Supplement), LB-079-LB-079, 2020 | 1 | 2020 |
| Microbubble mediated focused ultrasound therapy enhances the antitumor potency and durability of anti-PD-L1 checkpoint blockade D Goertz, W Cruz, S Bulner, A Wright, R Kerbel CANCER RESEARCH 80 (16), 2020 | | 2020 |
| Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer KA Khan, JL Ponce de Léon, M Benguigui, P Xu, A Chow, W Cruz-Muñoz, ... NPJ Breast Cancer 6 (1), 29, 2020 | 30 | 2020 |
| A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis KA Khan, RS Kerbel EMBO Molecular Medicine 12 (6), e12355, 2020 | 7 | 2020 |
| Construction of novel bispecific single-domain antibodies (BiSdAbs) with potent antiangiogenic activities X Liu, T Sun, Q Ge, J Zhu Pharmaceutical Fronts 2 (01), e64-e76, 2020 | 6 | 2020 |
| Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1 M Timaner, R Kotsofruk, Z Raviv, K Magidey, D Shechter, T Kan, ... Oncogene 39 (1), 187-203, 2020 | 43 | 2020 |
| Metronomic chemotherapy offsets HIFo induction upon maximum-tolerated dose in metastatic cancers L Schito, S Rey, P Xu, S Man, W Cruz-Muñoz, RS Kerbel | | 2020 |
| Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer E Reguera-Nuñez, P Xu, A Chow, S Man, F Hilberg, RS Kerbel Journal of Experimental & Clinical Cancer Research 38, 1-16, 2019 | 33 | 2019 |
